Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with sensitive epidermal growth factor receptor (EGFR) mutations are successfully treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, resistance to treatment inevitably occurs. Given lipid metabolic reprogramming is widely known...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Quanfu, Wang, Qiuguo, Li, Dong, Wei, Xiao, Jia, Yijuan, Zhang, Zheng, Ai, Bo, Cao, Xiaonian, Guo, Tao, Liao, Yongde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419820/
https://www.ncbi.nlm.nih.gov/pubmed/30876460
http://dx.doi.org/10.1186/s13046-019-1120-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419820/
https://www.ncbi.nlm.nih.gov/pubmed/30876460
http://dx.doi.org/10.1186/s13046-019-1120-4

Ejemplares similares